好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Beyond Disability: The Burden of Fatigue in CIDP
Neuromuscular and Clinical Neurophysiology (EMG)
P1 - Poster Session 1 (8:00 AM-9:00 AM)
9-007

To evaluate the impact of fatigue on health-related quality of life (HRQoL), work productivity, daily functioning, and employment status in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), independent of disability.

CIDP is an immune-mediated peripheral neuropathy characterized by distal and/or proximal weakness and sensory symptoms.

We analyzed matched physician–patient data from Adelphi’s CIDP Disease Specific Programme™ (France, Germany, Italy, Spain, United States, Japan; n=310; April 2022–April 2023). Disability was assessed by physicians using the INCAT score (0–10; higher scores = greater disability). Patients completed the FACIT-Fatigue (0–52; lower scores = greater fatigue), I-RODS (0–100; lower scores = greater daily activity limitations), EQ-5D-5L, and WPAI (0–100; higher scores = greater productivity loss) questionnaires. EQ-5D-5L utility values were derived using the UK value set, anchored at 0 (death) and 1 (perfect health). Associations of INCAT and FACIT-Fatigue with I-RODS, EQ-5D-5L, and WPAI were assessed using multiple linear regression; logistic regression was used for employment status (employed/ not employed).

The mean age of participants was 54.4 years (SD 12.6); 59.4% were male, and 48.2% were employed. Mean scores were 0.65 (SD 0.25) for EQ-5D-5L utility values, 35.2 (SD 10.5) for FACIT-Fatigue, 64.6 (SD 21.6) for I-RODS, and 2.8 (SD 2.0) for INCAT.

Across models, greater fatigue was independently associated with worse outcomes after adjustment for disability. Specifically, greater fatigue was linked to lower HRQoL (β = –0.016, 95% CI [–0.018, –0.014]), higher work productivity losses (β = –1.44, 95% CI [–1.90, –0.99]), more limitations in daily activities (β = 1.12, 95% CI [0.92, 1.32]), and lower employment rates (OR =1.06, 95% CI [1.02, 1.10]).

Fatigue substantially affects HRQoL, work productivity, daily activities, and employment in CIDP, independent of disability. These findings highlight an important clinical challenge and opportunity to explore strategies to mitigate this unmet need.

Authors/Disclosures
Dustin Nowacek, MD
PRESENTER
Dr. Nowacek has received personal compensation for serving as an employee of Argenx. Dr. Nowacek has or had stock in Argenx.
Swapna Karkare Swapna Karkare has received personal compensation for serving as an employee of argenx. Swapna Karkare has stock in argenx.
Arash Mahajerin, MD, MSCr Dr. Mahajerin has received personal compensation for serving as an employee of argenx. Dr. Mahajerin has stock in argenx.
Clemence Arvin-Berod, PharmD Dr. Arvin-Berod has received personal compensation for serving as an employee of argenx.
Lucas Van de Veire, MA Mr. Van de Veire has received personal compensation for serving as an employee of Services in Health Economics.
Jack Wright (Adelphi Real World) Jack Wright has received personal compensation for serving as an employee of Adelphi Real World.
Yasmin Taylor Yasmin Taylor has received personal compensation for serving as an employee of Adelphi Real World.
Rabiyah Sahar, PT, MSc Mrs. Sahar has received personal compensation for serving as an employee of Adelphi Real World.
Sarah Dewilde, PhD Dr. Dewilde has received personal compensation for serving as an employee of Services in Health Economics.
febe brackx Ms. brackx has received personal compensation for serving as an employee of Services in Health Economics.